Keywords: USA, FDA, Biosimilars, User fees, Consultation, Approval athway

US FDA consults on user fee program for biosimilar and interchangeable biologicals

Article | 10 May 2011

The US Food and Drug Administration is requesting input from stakeholders and the public relating to the development of a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in